Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol for early identification of cardiovascular disorders in cirrhosis, type 2 diabetes, and cardiotoxic treatment exposure
2021-003889-12Phase 3Active
- Sponsor
- Centro de Investigación Biomédica en Red
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of esmolol in cardiac morbidity (3 cohorts), sponsored by Centro de Investigación Biomédica en Red. Primary endpoints: Reduction in variability of left ventricular systolic function measurement with acute adrenergic blockade and Improved cardiovascular diagnosis. Started Dec 2021; status: active.
02
Drugs
esmolol
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on 2021-003889-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003889-12.